An autonomous device for measuring at least one characteristic of a fluid circulating in a conduit in a flow direction comprises a permanent magnetic field source, a magneto-electric converter and a processing circuit capable of using the electric charges supplied by the converter to supply a measurement of a characteristic of its environment. The source and the converter are placed in a stator and a rotor forming the device. The autonomous device further comprises attachment means allowing the stator to be fixedly placed in the conduit or at one end of the conduit, in a configuration in which the axis of rotation of the rotor is parallel to the flow direction. A control system may employ at least one such autonomous device.

An autonomous device for measuring at least one characteristic of a fluid circulating in a conduit in a flow direction comprises a permanent magnetic field source, a magneto-electric converter and a processing circuit capable of using the electric charges supplied by the converter to supply a measurement of a characteristic of its environment. The source and the converter are placed in a stator and a rotor forming the device. The autonomous device further comprises attachment means allowing the stator to be fixedly placed in the conduit or at one end of the conduit, in a configuration in which the axis of rotation of the rotor is parallel to the flow direction. A control system may employ at least one such autonomous device.

The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly in cancer stem cells. Particularly, the invention relates to compounds of Formula III to XIV for the treatment of cancer, such as breast and prostate cancer.

The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly in cancer stem cells. Particularly, the invention relates to compounds of Formula III to XIV for the treatment of cancer, such as breast and prostate cancer.

The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them highly advantageous for use in therapy, particularly in the treatment or prevention of cancer, a neovascular eye disease, inflammatory pain, or an inflammatory disease, such as, e.g., multiple sclerosis, rheumatoid arthritis or endometriosis.

##STR00001##

The present disclosure belongs to the technical field of plant extraction, and particularly relates to mangiferin and a preparation method thereof. The present disclosure includes activated carbon treatment and extraction of raw materials successively to obtain the mangiferin; the raw materials are mango leaves and/or almond leaves; the extraction is absolute methanol extraction, and the extraction is conducted at 60-65° C. Results of examples indicate that mangiferin obtained by the preparation method of mangiferin provided by the present disclosure has a purity of 98% to 99.5%, and mangiferin yield is as high as 66.7% of total mangiferin content in the mango leaves or almond leaves. The preparation method of mangiferin provided by the present disclosure is simple to operate, which obtains high-yield and highly pure mangiferin while reducing production costs of the mangiferin, and realizes the industrial production of the mangiferin.

The present disclosure belongs to the technical field of plant extraction, and particularly relates to mangiferin and a preparation method thereof. The present disclosure includes activated carbon treatment and extraction of raw materials successively to obtain the mangiferin; the raw materials are mango leaves and/or almond leaves; the extraction is absolute methanol extraction, and the extraction is conducted at 60-65° C. Results of examples indicate that mangiferin obtained by the preparation method of mangiferin provided by the present disclosure has a purity of 98% to 99.5%, and mangiferin yield is as high as 66.7% of total mangiferin content in the mango leaves or almond leaves. The preparation method of mangiferin provided by the present disclosure is simple to operate, which obtains high-yield and highly pure mangiferin while reducing production costs of the mangiferin, and realizes the industrial production of the mangiferin.

The invention provides 20-nor-salvinorin A, an analog of the kappa-opioid agonist salvinorin A. The 20-nor-salvinorin A is an active kappa-opioid modulator and can be used for treatment of medical conditions wherein modulation of the kappa-opioid receptor is medically indicated, such as pain, pruritis, depression, or inflammation, or conditions implicating perception and consciousness. 20-nor-salvinorin A can be less additive when used in treatment compared to a mu-opioid receptor agonist, and 20-nor-salvinorin A is more stable in vivo than is parent compound salvinorin A. The invention further provides synthetic intermediates and procedures for preparation of 20-nor-salvinorin A.

The invention provides 20-nor-salvinorin A, an analog of the kappa-opioid agonist salvinorin A. The 20-nor-salvinorin A is an active kappa-opioid modulator and can be used for treatment of medical conditions wherein modulation of the kappa-opioid receptor is medically indicated, such as pain, pruritis, depression, or inflammation, or conditions implicating perception and consciousness. 20-nor-salvinorin A can be less additive when used in treatment compared to a mu-opioid receptor agonist, and 20-nor-salvinorin A is more stable in vivo than is parent compound salvinorin A. The invention further provides synthetic intermediates and procedures for preparation of 20-nor-salvinorin A.

The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (I) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected from alumina and aluminum alkoxides and in a non-protic solvent wherein at least one carbon atom ortho to the hydroxy group in the hydroxy aryl compound is unsubstituted. The present application also includes compounds of Formula (I). ##STR00001##